References
- Hussain A, Tucker N, DeAngelis DD, et al. Guidelines for vismodegib in the management of periocular basal cell carcinoma. Can J Ophthalmol. 2019; pii: S0008-4182(19)30989-5. DOI:https://doi.org/10.1016/j.jcjo.2019.11.004
- Scalvenzi M, Costa C, Cappello M, et al. Reply to Woltsche N. et al. Managing adverse effects by dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor vismodegib: a single-centre experience. J Eur Acad Dermatol Venereol. 2019;33(4):e145–e147.
- Cox KF, Margo CE. Role of vismodegib in the management of advanced periocular basal cell carcinoma. Cancer Control. 2016;23(2):133–139.
- Scalvenzi M, Villani A, Mazzella C, et al. Vismodegib treatment in a HIV positive patient on antiretroviral therapy. Indian J Dermatol Venereol Leprol. 2018;84(6):758–760.
- Oliphant H, Laybourne J, Chan K, et al. Vismodegib for periocular basal cell carcinoma: an international multicentre case series. Eye (Lond). 2020. DOI:https://doi.org/10.1038/s41433-020-0778-3
- Sagiv O, Nagarajan P, Ferrarotto R, et al. Ocular preservation with neoadjuvant vismodegib in patients with locally advanced periocular basal cell carcinoma. Br J Ophthalmol. 2019;103(6):775–780.
- Wong KY, Fife K, Lear JT, et al. Vismodegib for locally advanced periocular and orbital basal cell carcinoma: a review of 15 consecutive cases. Plast Reconstr Sur Glob Open. 2017;5(7):e1424.